• Meropenem Trihydrate: Metabolomic Tools for Resistance Profi

  2026-07-14

  Explore how Meropenem trihydrate serves as a cornerstone for antibiotic resistance studies and metabolomic phenotyping. This article uncovers unique workflow strategies and practical assay insights for researchers investigating gram-negative pathogens.

• Patient-Derived Gastric Cancer Assembloids Illuminate Drug R

  2026-07-14

  This study introduces a physiologically relevant assembloid model combining patient-matched gastric tumor organoids and stromal cell subpopulations. By closely mimicking the tumor microenvironment, the model reveals how stromal heterogeneity impacts gene expression and drug sensitivity, supporting more predictive cancer research and personalized therapy development.

• Novel PDK4 Inhibitors for Metabolic Disease: Study Insights

  2026-07-13

  This article examines a recent medicinal chemistry study that identifies new allosteric inhibitors of pyruvate dehydrogenase kinase 4 (PDK4), with promising activity against metabolic and allergic diseases. The research offers mechanistic and preclinical evidence for targeting PDK4, providing new scaffolds and protocols for drug development.

• Risedronate Sodium (SKU A5293): Reliable Solutions for Assay

  2026-07-13

  This article provides scenario-driven, evidence-based guidance for using Risedronate Sodium (SKU A5293) in cell viability, proliferation, and cytotoxicity assays. Drawing on recent literature and rigorously validated protocols, we address real-world laboratory challenges and demonstrate how APExBIO’s Risedronate Sodium delivers reproducible, sensitive, and cost-efficient results in bone metabolism and cancer research.

• Thioguanine: Precision Use in Cancer and Antiviral Assays

  2026-07-12

  Thioguanine (6-thioguanine) stands apart as a dual-action antitumor and antiviral agent, with validated efficacy in inhibiting cancer cell proliferation and EV71 virus replication. This guide details experimental workflows, protocol parameters, and troubleshooting strategies—enabling researchers to leverage APExBIO's high-purity Thioguanine for reproducible, publication-ready results.

• Optimizing DNA Synthesis: From dNTP Precision to LNP Deliver

  2026-07-10

  This article provides translational researchers with a mechanistic and strategic roadmap for advancing DNA synthesis and delivery, spotlighting the pivotal role of equimolar dNTP mixtures in molecular biology and the emerging challenges in lipid nanoparticle (LNP)–mediated nucleic acid delivery. Highlighting recent evidence on cholesterol’s impact on LNP intracellular trafficking, we guide researchers in selecting and applying high-purity nucleotide reagents—such as APExBIO’s 10 mM dNTP (2'-deoxyribonucleoside-5'-triphosphate) Mixture—within workflows that demand both fidelity and adaptability. The discussion moves beyond traditional product guides by integrating new mechanistic insights and actionable experimental guidance, offering a forward-looking perspective at the interface of DNA synthesis and therapeutic delivery.

• Biohybrid Microrobots: Adaptive Locomotion for Tumor Targeti

  2026-07-09

  The referenced study introduces a magnetically guided biohybrid microrobot platform leveraging the natural deformability and motility of Euglena gracilis, enhanced with magnetic architectures for multimodal navigation. This innovation enables precise barrier penetration and multifunctional tumor therapy, offering new prospects for adaptive, drug-free microrobotic interventions in complex biological environments.

• Canagliflozin as an SGLT2 Inhibitor: Mitochondrial and Renal

  2026-07-09

  Canagliflozin stands out as a selective SGLT2 inhibitor not only for its ability to reduce renal glucose reabsorption, but also for its direct remodeling of mitochondrial networks in diabetic kidney disease models. This article bridges advanced workflow optimization with troubleshooting tips, empowering metabolic disease researchers to maximize reproducibility and translational relevance with APExBIO’s Canagliflozin.

• Mestranol Induces Reversible Lysosomal Stress in Zebrafish M

  2026-07-08

  This study uncovers how mestranol, a synthetic estrogen, triggers a reversible lysosomal storage–like state in zebrafish microglia, without affecting cell number or apoptosis. The findings offer a live, pharmacologically controlled model to investigate microglial lysosomal dysfunction, with important implications for understanding neuroimmunotoxicity and environmental estrogen exposure.

• CerS6-Driven Ceramide and Mitochondrial Injury in Stress-Exp

  2026-07-08

  Liu et al. (2024) delineate a mechanism by which restraint stress disrupts hepatic ceramide metabolism, implicating CerS6-mediated C16:0 ceramide in mitochondrial damage. Their integrative rat and hepatocyte models illuminate the AMPK/p38 MAPK pathway as a regulatory axis, offering new directions for stress-related liver injury research.

• CGP 55845 Hydrochloride: Unlocking GABAB Receptor Antagonism

  2026-07-07

  Explore how CGP 55845 hydrochloride, a potent GABAB receptor antagonist, enables advanced investigation of neurotransmitter release modulation and synaptic transmission in vitro. This article uniquely examines its mechanistic versatility and assay implications, offering fresh insights beyond standard workflows.

• Treponema pallidum Drives Hepatocyte Apoptosis via Mitochond

  2026-07-07

  This study reveals that Treponema pallidum induces intrinsic apoptosis in hepatocytes by promoting mitochondrial reactive oxygen species (ROS) accumulation and cardiolipin peroxidation. The findings elucidate a key mechanism underlying hepatic injury during syphilis and highlight mitochondrial dysfunction as a central pathogenic event.

• Homoharringtonine: Rapid SARS-CoV-2 Clearance in Preclinical

  2026-07-06

  A recent study demonstrates homoharringtonine’s potent, rapid inhibition of SARS-CoV-2 across cell, animal, and human models, supporting its potential as a first-line antiviral for future coronavirus epidemics. This work highlights robust mechanistic and translational advances, yet also outlines the need for expanded safety and efficacy data beyond initial trials.

• Citrate Buffer Molarity Shapes Luciferase mRNA-LNP Efficacy

  2026-07-06

  This study explores how the molarity of citrate buffer used during lipid nanoparticle (LNP) formulation impacts the cellular uptake and transfection efficiency of firefly luciferase mRNA. The results demonstrate that while traditional quality attributes may remain unchanged, higher citrate molarity can subtly diminish transfection outcomes, underscoring the importance of buffer optimization for RNA delivery technologies.

• Nullscript: Precision HDAC Inhibitor for Cardiac Research

  2026-07-05

  Nullscript is a histone deacetylase inhibitor that selectively inhibits HDACs without transcriptional activation. Studies show it markedly reduces myocardial infarct size in vivo, with a distinct inactivity profile compared to scriptaid. Its chemical stability and solubility parameters make it suitable for advanced cardiac and neurodegenerative research.

14905 records 1/994 page Next 12345 下5页 Last page